Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in EGFR-TKI Resistant NSCLC
NCT05573373Phase 1Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pamiparib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Objective Response Rate at 8 weeks. Started Dec 2022; status: recruiting.
02
Drugs
pamiparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05573373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573373.